Metastatic Disease of the Nervous System
224,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Gebundenes Buch

Metastatic Disease of the Nervous System, Volume 149, begins with an overview of the impact and range of direct neoplastic involvement of the central and peripheral nervous system, comprehensively reviewing all aspects of brain metastases, from clinical, radiological and neuropathological manifestations, to the roles of surgery, radiation, systemic and palliative therapy in their management, and the complications of these interventions. The clinical manifestations, diagnosis and treatment of leptomeningeal, dural, spinal epidural and plexus metastases are also covered in detail.
Covers all…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Metastatic Disease of the Nervous System, Volume 149, begins with an overview of the impact and range of direct neoplastic involvement of the central and peripheral nervous system, comprehensively reviewing all aspects of brain metastases, from clinical, radiological and neuropathological manifestations, to the roles of surgery, radiation, systemic and palliative therapy in their management, and the complications of these interventions. The clinical manifestations, diagnosis and treatment of leptomeningeal, dural, spinal epidural and plexus metastases are also covered in detail.

Covers all aspects of brain metastases, from clinical, radiological and neuropathological manifestations, to the roles of surgery, radiation, systemic and palliative therapy Presents a multidisciplinary review of the evidence regarding accuracy of diagnostic testing and evidence-based reviews of therapies Addresses metastatic diseases of the nervous system for residents, fellows and clinicians in neurology and oncology
Autorenporträt
Dr. Schiff and his colleagues have conducted several dozen clinical trials assessing new treatments for glioblastoma, anaplastic gliomas, low-grade gliomas, brain lymphomas, brain metastases, and meningiomas. These trials have included treatment with new cytotoxic chemotherapy drugs, signal transduction inhibitors, radiation sensitizers, brachytherapy and radiosurgery, anti-angiogenesis agents, differentiation agents, monoclonal antibodies, and targeted immunotoxins. A second research focus is the cause of gliomas and brain lymphoma. Dr. Schiff has studied risk factors for the development of brain lymphoma in patients with intact immune systems, including the association between organ transplantation and the subsequent development of glioma. Spinal cord disease in cancer patients is another area of ongoing research, in particular the diagnostic role of MRI and the optimal management of metastatic spinal disease.